Health professionals and advocates shared experiences and insights on the critical importance of Black participation in ...

In a study published online July 9 in Blood Cancer Discovery, real-world outcomes are described for teclistamab, a ...

After 12 weeks of treatment, 75% of per-protocol patients receiving 0.05% urcosimod showed greater than 80% reduction in ...

University of New Mexico researchers have received funding to launch an early-stage clinical trial of a vaccine engineered to ...

NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the “Company”), and a clinical stage, leading global ...

Hengrui Pharma and Kailera Therapeutics have reported positive topline data from the former’s Phase III trial (HRS9531-301) ...

Rahway, New Jersey Wednesday, July 16, 2025, 17:30 Hrs [IST] ...

Tevogen Bio Holdings Inc. (Nasdaq: TVGN) is doubling down on its AI capabilities following the successful launch of its proprietary PredicTcell™ platform. The company announced plans to expand its ...

Suven Life Sciences has a portfolio of advanced-stage clinical candidates and research programs designed for CNS disorders ...

PYPD PolyPid Ltd. (NASDAQ:PYPD) is a late clinical stage biopharma company focused on developing locally administered, prolonged-release therapeutics using its proprietary Polymer-Lipid Encapsulation ...

Real-world analysis reveals that undetectable CD20 expression worsens outcomes for patients treated with epcoritamab and ...

Tony Newberne is a high-risk multiple myeloma survivor. He is also a CPT, dietary manager, and patient advocate for several ...